


## Cisd2 agonist 1

<b>Cat. No.:</b>	HY-155538		
<b>CAS No.:</b>	2916371-54-3		
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>13</sub> FN <sub>2</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	308.33		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (324.33 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	3.2433 mL	16.2164 mL	32.4328 mL
		5 mM	0.6487 mL	3.2433 mL	6.4866 mL
10 mM		0.3243 mL	1.6216 mL	3.2433 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (8.11 mM); Clear solution; Need ultrasonic  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (8.11 mM); Clear solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Cisd2 agonist 1 (Compound 4q) is a Cisd2 agonist (EC <sub>50</sub> : 34 nM). Cisd2 agonist 1 enhances the Cisd2 expression and improves the pathological changes in the fatty livers. Cisd2 agonist 1 has good metabolic stability. Cisd2 agonist 1 can be used for research of NAFLD <sup>[1]</sup> .
--------------------	--

### REFERENCES

[1]. Yao CH, et al. Discovery of tetrasubstituted thiophenes as Cisd2 activators: A potential novel therapeutic option in nonalcoholic fatty liver disease. Eur J Med Chem. 2023 Oct 5;258:115583.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA